Jane Sosabowski

Prof. Jane Sosabowski


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Theranostics
Verified
Journal Article
Open access
FFFarid N. Faruqu
Farid N. Faruqu
JWJulie Tzu-Wen Wang
Julie Tzu-Wen Wang
Lizhou XuLizhou Xu
Lizhou Xu
LMLuke McNickle
Luke McNickle
ECEden Ming-Yiu Chong
Eden Ming-Yiu Chong
KAKhuloud T. Al-Jamal
Khuloud T. Al-Jamal
Extracellular vesicles, in particular exosomes, have recently gained interest as novel drug delivery vectors due to their biological origin and inherent intercellular biomolecule delivery capability. An in-depth knowledge of their in vivo biodistribution is therefore essential. This work aimed to develop a novel, reliable and universal method to radiolabel exosomes to study their in vivo biodistribution.

2 April 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
PLPeter Laverman
Peter Laverman
LJLieke Joosten
Lieke Joosten
AEAnnemarie Eek
Annemarie Eek
SRSusan Roosenburg
Susan Roosenburg
Petra KolencPetra Kolenc
Petra Kolenc
OBOtto C. Boerman
Otto C. Boerman
Purpose Cholecystokinin 2 (CCK-2) receptor overexpression has been demonstrated in various tumours such as medullary thyroid carcinomas and small-cell lung cancers. Due to this high expression, CCK-2 receptors might be suitable targets for radionuclide imaging and/or radionuclide therapy. Several CCK-2 receptor-binding radiopeptides have been developed and some have been tested in patients. Here we aimed to compare the in vivo tumour targeting properties of 12 111In-labelled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated gastrin/CCK2 receptor-binding peptides. Methods Two CCK8-based peptides and ten gastrin-based peptide analogues were tested. All peptides were conjugated with DOTA and labelled with 111In. Biodistribution studies were performed in mice with subcutaneous CCK2/gastrin receptor-expressing tumours and with receptor-negative tumours contralaterally. Biodistribution was studied by counting dissected tissues at 1 and 4 h after injection. Results Both the CCK analogues displayed relatively low tumour uptake (approximately 2.5%ID/g) as compared to minigastrin analogues. Two linear minigastrin peptides (MG0 and sargastrin) displayed moderate tumour uptake at both 1 and 4 h after injection, but also very high kidney uptake (both higher than 48%ID/g). The linear MG11, lacking the penta-Glu sequence, showed lower tumour uptake and also low kidney uptake. Varying the N-terminal Glu residues in the minigastrin analogues led to improved tumour targeting properties, with PP-F11 displaying the optimal biodistribution. Besides the monomeric linear peptides, a cyclized peptide and a divalent peptide were tested. Conclusion Based on these studies, optimal peptides for peptide receptor radionuclide targeting of CCK2/gastrin receptor-expressing tumours were the linear minigastrin analogue with six D-Glu residues (PP-F11), the divalent analogue MGD5 and the cyclic peptide cyclo-MG1. These peptides combined high tumour uptake with low kidney retention, and may therefore be good candidates for future clinical studies.

29 April 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MOMeltem Ocak
Meltem Ocak
AHAnna Helbok
Anna Helbok
CRChristine Rangger
Christine Rangger
Petra KolencPetra Kolenc
Petra Kolenc
BNBerthold A. Nock
Berthold A. Nock
Clemens DecristoforoClemens Decristoforo
Clemens Decristoforo

1 February 2012 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
PLPeter Laverman
Peter Laverman
JSJane Sosabowski
Jane Sosabowski
OBOtto C. Boerman
Otto C. Boerman
Wim J.G. OyenWim J.G. Oyen
Wim J.G. Oyen
Radiolabelled receptor-binding peptides targeting receptors (over)expressed on tumour cells are widely under investigation for tumour diagnosis and therapy. The concept of using radiolabelled receptor-binding peptides to target receptor-expressing tissues in vivo has stimulated a large body of research in nuclear medicine. The 111In-labelled somatostatin analogue octreotide (OctreoScan™) is the most successful radiopeptide for tumour imaging, and was the first to be approved for diagnostic use. Based on the success of these studies, other receptor-targeting peptides such as cholecystokinin/gastrin analogues, glucagon-like peptide-1, bombesin (BN), chemokine receptor CXCR4 targeting peptides, and RGD peptides are currently under development or undergoing clinical trials. In this review, we discuss some of these peptides and their analogues, with regard to their potential for radionuclide imaging of tumours.

20 April 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LALuigi Aloj
Luigi Aloj
MAMichela Aurilio
Michela Aurilio
VRValentina Rinaldi
Valentina Rinaldi
LDLaura D’ambrosio
Laura D’ambrosio
Diego TesauroDiego Tesauro
Diego Tesauro
MJMarion de Jong
Marion de Jong

3 August 2006 in Nature Protocols
Verified
Journal Article
Closed access
JSJane Sosabowski
Jane Sosabowski
SMStephen J Mather
Stephen J Mather